

Declaration of Dr. S. Jamal Mustafa
Regarding U.S. Patent No. 6,645,513

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**PETITION FOR INTER PARTES REVIEW
OF U.S. PATENT NO. 6,645,513**

DECLARATION OF S. JAMAL MUSTAFA, Ph.D.

Declaration of Dr. S. Jamal Mustafa
Regarding U.S. Patent No. 6,645,513

I, S. Jamal Mustafa, Ph.D., declare as follows:

1. The opinions set forth below are based on my over 42 years of experience as an expert in biochemistry and pharmacology and on the review of materials discussed herein.

I. BACKGROUND AND QUALIFICATIONS

2. My *curriculum vitae* (“CV”) (a copy of which is attached) highlights my education, experience, and qualifications as an expert in biochemistry and pharmacology. Some of the information relevant to this case is summarized below.

3. I received a Bachelor of Science (B.S.) degree in Chemistry from Lucknow University in 1962, a Master of Science (M.S.) degree in Biochemistry from Lucknow University in 1965, and a Doctorate (Ph.D.) degree in Biochemistry from Lucknow University in 1970.

4. I was an Assistant Dean for Research and Assistant Vice President for Research in the Health Sciences Center at West Virginia University (WVU) in Morgantown, WV, positions I have held since 2005 and 2008 until June 30, 2015, respectively. I am also a Professor in the Department of Physiology & Pharmacology of the WVU School of Medicine, and an Adjunct Professor in the WVU School of Pharmacy, and have been since 2005. Through these programs, I am teaching graduate, medical and pharmacy courses in pharmacology.

Declaration of Dr. S. Jamal Mustafa
Regarding U.S. Patent No. 6,645,513

5. From 1980 to 2005, I worked as a Professor or Adjunct Professor in a number of departments of the School of Medicine at East Carolina University, including the Heart Center and the Departments of Pharmacology, Surgery, Medicine, and Physiology. In the past, I have also taught pharmacology courses at the University of South Alabama College of Medicine, and East Carolina University School of Medicine after finishing my post-doctoral training at the University of Virginia, School of Medicine (1971-74).

6. I have participated as Principal Investigator in over thirty grant-based research projects. My present research with the Health Sciences Center involves identifying and studying the role of adenosine receptors in normal and diseased tissues, and studying the roles of second messengers in the regulation of adenosine receptor expression, mostly in heart and lung.

7. Professional honors that I have received while at WVU include the Chancellor's Award for Outstanding Achievement in Research and Scholarly Activities in April 2013, the Robert C. Byrd Professorship in March, 2010, and the Award for Excellence in Research from School of Medicine in April, 2008. As further detailed in my CV, other Professional honors that I have received include: Lifetime Achievement Award in Research and Creative Activities from East Carolina University, June, 2003; First Award for Excellence in Basic Research from East Carolina University School of Medicine, May, 1997.

8. I have authored or co-authored over 200 articles published in scientific journals on the subject of adenosine, its derivatives, or cellular activity related to adenosine receptors. In addition, I have contributed to at least thirty review articles and/or textbooks, and am on or have been on the Editorial Board of a number of peer-reviewed journals, including *Reactive Oxygen Species* and *American Journal of Pharmacology and Toxicology*, *Vascular Pharmacology*, as well as many others.

II. COMPENSATION, PREVIOUS TESTIMONY, AND RELATIONSHIP TO THE PARTIES

9. I am being compensated at an hourly rate of \$ 350 for the time I spend studying materials and issues associated with this matter and for the time I spend providing testimony. This rate is my standard consulting rate. My compensation is not contingent upon the outcome of this matter.

10. It is my understanding that University of Massachusetts is the assignee of the '513 patent. Prior to this matter, I have not worked for University of Massachusetts, and am aware of no financial interest that I have in the University of Massachusetts.

11.

III. MATERIALS CONSIDERED

12. I have reviewed the following materials:

Declaration of Dr. S. Jamal Mustafa
Regarding U.S. Patent No. 6,645,513

Exhibit No.	Description
1002	U.S. Patent No. 6,645,513 to Dobson <i>et al.</i>
1014	Kathryn M. Neurath et al., <i>AMP-Dependent Protein Kinase Alpha 2 Isoform Promotes Hypoxia-Induced VEGF Expression in Human Glioblastoma</i> , 53 <i>Glia</i> 733, 733–743 (2006).
1015	Geoffrey Burnstock et al., <i>Purinergic Signaling in Healthy and Diseased Skin</i> , 132 <i>J. Invest. Dermatol</i> 526, 526–546 (2012).
1019	R H. Koizumi et al., <i>Adenosine Deaminase in Human Epidermis from Healthy and Psoriatic Subjects</i> , 275 <i>Arch Dermatol Res</i> 310, 310-14 (1983).

IV. Adenosine Monophosphate is an Angiogenic Factor

13. Adenosine Monophosphate (AMP) is known to be an angiogenic factor. (Ex. 1014). The property of AMP as an angiogenic factor is inherent and would not have changed over time. In other words, the inherent function of AMP as an angiogenic factor has not changed since 1998.

V. Adenosine Metabolizes in the Epidermis

14. It is my understanding that human skin includes many layers, including an outer, epidermal layer, which covers multiple inner layers (including the dermal layer). (Ex. 1002, col. 1, ll. 25-30). The '513 patent describes the skin as having “a surface layer, known as the epidermis, and a deeper connective tissue layer, known as the dermis.” (*Id.*)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.